Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Alpine Woods Capital Investors LLC

Alpine Woods Capital Investors LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 31.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,413 shares of the medical research company's stock after selling 4,267 shares during the period. Thermo Fisher Scientific accounts for approximately 1.2% of Alpine Woods Capital Investors LLC's investment portfolio, making the stock its 29th biggest holding. Alpine Woods Capital Investors LLC's holdings in Thermo Fisher Scientific were worth $4,684,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after buying an additional 461 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 32.1% during the fourth quarter. Proficio Capital Partners LLC now owns 1,466 shares of the medical research company's stock valued at $763,000 after buying an additional 356 shares during the last quarter. Finally, Moran Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.4% during the fourth quarter. Moran Wealth Management LLC now owns 1,089 shares of the medical research company's stock valued at $567,000 after buying an additional 26 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on TMO. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and lowered their price target for the company from $500.00 to $460.00 in a report on Tuesday. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research note on Tuesday, June 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $600.30.

Thermo Fisher Scientific Price Performance

TMO traded up $4.29 during trading on Friday, reaching $435.02. The company's stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a fifty day simple moving average of $409.39 and a two-hundred day simple moving average of $476.23. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a market cap of $164.22 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period last year, the company posted $5.11 EPS. The business's revenue was up .2% on a year-over-year basis. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.